WO2000006735A8 - Interferon alpha hybrids - Google Patents

Interferon alpha hybrids

Info

Publication number
WO2000006735A8
WO2000006735A8 PCT/US1999/015284 US9915284W WO0006735A8 WO 2000006735 A8 WO2000006735 A8 WO 2000006735A8 US 9915284 W US9915284 W US 9915284W WO 0006735 A8 WO0006735 A8 WO 0006735A8
Authority
WO
WIPO (PCT)
Prior art keywords
interferon alpha
polypeptides
hybrids
alpha hybrids
peptides
Prior art date
Application number
PCT/US1999/015284
Other languages
French (fr)
Other versions
WO2000006735A1 (en
Inventor
Kathryn C Zoon
Renqiu Hu
Joseph B Bekisz
Mark P Hayes
Original Assignee
Us Health
Kathryn C Zoon
Renqiu Hu
Joseph B Bekisz
Mark P Hayes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, Kathryn C Zoon, Renqiu Hu, Joseph B Bekisz, Mark P Hayes filed Critical Us Health
Priority to US09/744,754 priority Critical patent/US6685933B1/en
Priority to AU49722/99A priority patent/AU4972299A/en
Publication of WO2000006735A1 publication Critical patent/WO2000006735A1/en
Publication of WO2000006735A8 publication Critical patent/WO2000006735A8/en
Priority to US10/615,723 priority patent/US7235232B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Hybrid human interferon-α polypeptides, and the corresponding nucleic acid molecules, are disclosed. Pharmaceutical compositions comprising these peptides, and the use of these polypeptides to treat viral disease and regulate cell growth are also provided.
PCT/US1999/015284 1998-07-28 1999-07-06 Interferon alpha hybrids WO2000006735A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US09/744,754 US6685933B1 (en) 1998-07-28 1999-07-06 Interferon α hybrids
AU49722/99A AU4972299A (en) 1998-07-28 1999-07-06 Interferon alpha hybrids
US10/615,723 US7235232B2 (en) 1998-07-28 2003-07-08 Interferon alpha hybrids

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9440798P 1998-07-28 1998-07-28
US60/094,407 1998-07-28

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US09/744,754 A-371-Of-International US6685933B1 (en) 1998-07-28 1999-07-06 Interferon α hybrids
US09744754 A-371-Of-International 1999-07-06
US10/615,723 Division US7235232B2 (en) 1998-07-28 2003-07-08 Interferon alpha hybrids

Publications (2)

Publication Number Publication Date
WO2000006735A1 WO2000006735A1 (en) 2000-02-10
WO2000006735A8 true WO2000006735A8 (en) 2000-04-06

Family

ID=22244996

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1999/014749 WO2000006596A2 (en) 1998-07-28 1999-06-29 Interferon alpha hybrids
PCT/US1999/015284 WO2000006735A1 (en) 1998-07-28 1999-07-06 Interferon alpha hybrids

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US1999/014749 WO2000006596A2 (en) 1998-07-28 1999-06-29 Interferon alpha hybrids

Country Status (2)

Country Link
AU (2) AU4845699A (en)
WO (2) WO2000006596A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014028502A1 (en) * 2012-08-13 2014-02-20 ImmunGene Inc. Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2824333B1 (en) 2001-05-03 2003-08-08 Genodyssee NOVEL POLYNUCLEOTIDES AND POLYPEPTIDES OF IFN ALPHA 5
WO2003009632A1 (en) 2001-07-13 2003-01-30 Mitsubishi Denki Kabushiki Kaisha Wireless telephone and wireless telephone system
CA2521567A1 (en) * 2003-05-01 2004-11-11 Millennium Diet And Nutriceuticals Limited Measurement of distribution of macular pigment
WO2006076014A2 (en) * 2004-04-30 2006-07-20 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Interferon-alpha constructs for use in the treatment of sars
CN111499718B (en) * 2019-01-30 2022-06-14 复旦大学 Human alpha interferon receptor binding related site mutant and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0626448A3 (en) * 1993-05-26 1998-01-14 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Process for preparing and purifying alpha-interferon

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014028502A1 (en) * 2012-08-13 2014-02-20 ImmunGene Inc. Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases

Also Published As

Publication number Publication date
WO2000006596A2 (en) 2000-02-10
AU4972299A (en) 2000-02-21
WO2000006735A1 (en) 2000-02-10
AU4845699A (en) 2000-02-21

Similar Documents

Publication Publication Date Title
WO2000024365A8 (en) Treatment of skin with adenosine or adenosine analog
ATE237312T1 (en) NUCLEIC ACID COMPLEXES ENCAPSULATED IN LIPOSOMES
CA2097185A1 (en) Viral recombinant vectors for expression in muscle cells
CA2168029A1 (en) Prosaposin and cytokine-derived peptides as therapeutic agents
AU2926401A (en) Novel chimeric proteins and methods for using the same
CA2323086A1 (en) Regulation of endogenous gene expression in cells using zinc finger proteins
WO1997009343A3 (en) Antagonists of the oncogenic activity of the protein mdm2, and use thereof in the treatment of cancers
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
DE69819124D1 (en) LYOPHILIZATION OF CULTIVATED, HUMAN CELLS FOR THE PRESERVATION OF RNA AND DNA
CA2255539A1 (en) Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma
WO1998058957A3 (en) Disulfide cross-linked glycoprotein hormone analogs, their preparation and use
ZA200108414B (en) Akt nucleic acids, polypeptides, and uses thereof.
WO2002044197A3 (en) Cytokine receptor binding peptides
WO2000006735A8 (en) Interferon alpha hybrids
CA2094275A1 (en) Methods and compositions for the treatment of cell proliferation disorders
CA2278808A1 (en) Methods for cultivating cells and propagating viruses
AU3982497A (en) Double-stranded rna dependent protein kinase derived peptides to promote proliferation of cells and tissues in controlled manner
AU7437900A (en) Cryopreserved amniotic human cells for future therapeutic, diagnostic, genetic and others uses
AU9269898A (en) Artificial viruses derived from papillomavirus, and their uses, in particular gene therapy
PT1140023E (en) INTEGRATING COCLEAR FORMULATIONS OF PROTEIN-DNA AND METHODS OF CELLULAR TRANSFORMATION
AU3390995A (en) Novel implant and novel vector for the treatment of acquired diseases
EP0821969A3 (en) Medicinal Composition comprising TCF-II
IT9020072A0 (en) HUMAN CELLS FOR THE HIGH EXPRESSION OF GENES INSERTED IN EPISOMIAL RECOMBINANT DNA, THEIR PREPARATION AND THEIR USE
CA2385872A1 (en) Gene transfer in human lymphocytes using retroviral scfv cell targeting
AU5876899A (en) Polymorphisms in the human alpha4 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 06/2000 UNDER (51) REPLACE "C12N 15/29" BY "C12N 15/21"

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 09744754

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase